Introduction
Peroxisome proliferator-activated receptors (PPARs) are members of the family of ligand-activated transcription factors that includes receptors for steroids, thyroid hormone, retinoic acid, and vitamin D. Three subtypes of PPAR have been identified and cloned: PPAR-a, PPAR-b, and PPAR-g. PPAR-a is a key regulator of lipid metabolism. Specifically, activation of PPAR-a results in proliferation of peroxisomes and the induction of genes involved in b-oxidation of fatty acids (Desvergne and Wahli, 1999) . PPAR-b is ubiquitously expressed and has been implicated in the repression of PPAR-a and -g transcriptional activity (Shi et al., 2002) as well as in wound healing (Di-Poi et al., 2002) . PPARg is highly expressed in adipose tissue and has a dominant regulatory role in adipocyte differentiation (Tontonoz et al., 1994; Spiegelman and Flier, 1996) . In humans, PPAR-g is expressed in multiple other tissues, including the breast, colon, lung, ovary, and placenta (Lambe and Tugwood, 1996; Elstner et al., 1998; Mueller et al., 1998; Sarraf et al., 1998) . Recently, PPAR-g has been described as a negative regulator of macrophage function. PPAR-g activation suppresses the production of inflammatory cytokines/chemokines, metalloproteases, and nitric oxide synthesis (Jiang et al., 1998; Ricote et al., 1998) . The activation of PPAR-g can also promote monocyte differentiation Tontonoz et al., 1998) . Several ligands have been described for PPAR-g, including the synthetic thiazolidinedione (TZD) class of insulin-sensitizing agents, such as Troglitazone (Tro), Rosiglitazone (Rosi), and Pioglitazone (Pio), and certain nonsteroidal anti-inflammatory drugs. Rosi and Pio are currently in clinical use for the treatment of type-II diabetes mellitus based on their ability to reverse insulin resistance. Tro was also prescribed for type-II diabetes for several years (Spiegelman, 1998) and was shown to be effective at doses of 400-800 mg/day. Although the drug was generally well tolerated at these doses, idiosyncratic liver toxicity led to its withdrawal from clinical use (Watkins and Whitcomb, 1998) . Additionally, a number of natural ligands for PPAR-g have been identified, including the prostanoids, prostaglandin D 2 , 15-deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 ), and certain polyunsaturated fatty acids (reviewed in Berger and Moller, 2002) . Whether these natural ligands regulate PPAR-g in vivo is yet to be determined. PPARs heterodimerize with retinoid X receptors (RXR), forming a complex that regulates gene expression. Ligand binding results in a conformational change in the receptor that permits the dissociation of corepressors and concomitant association of coactivators. The heterodimer-coactivator complex binds to specific response elements (PPREs) in the promoter regions of target genes to regulate transcription. It has been demonstrated that PPAR-g and -a recognize distinct PPREs (Kassam et al., 1998) .
Cancer cells have been shown to dedifferentiate prior to acquiring a proliferative and antiapoptotic phenotype (Bloch, 1984; Pierce and Speers, 1988) . Therefore, the induction and maintenance of a differentiated state has been an important strategy in the search for cancer therapeutics. In addition to adipogenic and antiinflammatory effects, PPAR-g activation has been shown to be antiproliferative by virtue of its differentiation-promoting effects. This suggests that activators of PPAR-g might be useful in slowing or arresting the proliferation of dedifferentiated tumor cells. In support of this concept, PPAR-g agonists inhibit the proliferation of human breast, prostate, colon, and pituitary cancer cells in vitro (Elstner et al., 1998; Kubota et al., 1998; Mueller et al., 1998; Heaney et al., 2002) . In addition, naturally occurring somatic mutations in the gene encoding PPAR-g have been found in a proportion of sporadic colo-rectal carcinomas (Sarraf et al., 1999) . One of these mutations results in the truncation of the ligand-binding domain and the others result in mutant receptors defective in ligand binding. These findings further support a role for active PPAR-g as a potential tumor suppressor. In spite of promising results obtained from in vitro studies, there are few studies examining the efficacy of PPAR-g agonists in animal models of tumorigenesis, and none in lung cancer. Even though these agonists inhibit cell growth, the molecular mechanism(s) of their action are still not clear.
In the present study, we have demonstrated that the activation of PPAR-g in NSCLC cells resulted in growth inhibition due to G 0 /G 1 cell cycle arrest through the downregulation of G 1 cyclins D and E. In addition, PPAR-g ligands induced sustained Erk1/2 activation in NSCLC cells, suggesting the activation of a differentiation-inducing pathway. Finally, the treatment of NSCLC tumor-bearing SCID mice with a PPAR-g ligand inhibited tumor growth and metastasis. Collectively, our data demonstrate that activation of PPAR-g impedes lung tumor progression and suggests PPAR-g ligands as potential therapeutic agents for NSCLC.
Results

Expression of PPAR-g in NSCLC primary tumors and cell lines
To determine if PPAR-g might represent a relevant transcription factor in NSCLC, we first assessed the expression of PPAR-g in primary tumors and surrounding normal lung tissue from 22 patients with NSCLC.
We found that PPAR-g protein, as determined by immunohistochemistry, was expressed at high levels in all the tumor samples tested relative to that observed in surrounding nondiseased lung tissue (Figure 1a ). Homogenized tissue samples from all the above tumors and corresponding normal tissue, subjected to SDS-PAGE and Western immunoblot analysis demonstrated similar results (Figure 1b) . In addition, substantial expression of PPAR-g protein was detected in all NSCLC cell lines assessed (H522, Hop62, H358, and A549) (Figure 1c ).
PPAR-g activation correlates with inhibition of cell growth
To assess PPAR-g activation and its effects on tumor cell growth, we utilized cultured A549 human lung adenocarcinoma cells. Ligand-dependent PPAR-g transcriptional activation in A549 cells was determined by a luciferase-based reporter-gene transactivation assay. In this assay, the PPAR-g response element (PPRE) isolated from the fatty acid transporter protein (FATP) gene was used to drive the expression of the reporter gene. Tro treatment induced PPAR-g transcriptional activity in A549 cells as assessed by PPRE-driven luciferase activity (Figure 2a) . Specifically, PPAR-g transcriptional activity increased with increasing concentrations of Tro with a peak luciferase activity noted at a dose of 15 mm (Figure 2a) . To evaluate the effects of PPAR-g activation on tumor cell growth, we determined the growth kinetics of A549 cells in the presence or absence of Tro. Cells were continuously cultured in the presence of 10% serum with varying concentrations of Tro, and cell numbers were determined by coulter Figure 2b ). This suppression of cell number was dose-and time-dependent, which is consistent with a slow cytostatic effect, rather than a rapid cytotoxic response to Tro. WY14643 (20 mm), an agonist for PPAR-a but not PPAR-g, had no effect on the growth of A549 cells (Figure 2b ), demonstrating the specificity of the PPAR-g agonist to mediate this effect. Furthermore, Tro also inhibited serum-stimulated growth of H520, a squamous cell carcinoma cell line (Figure 2c ). Taken together, these results suggest that treatment with a PPAR-g agonist (Tro) results in growth suppression of tumor cells in vitro.
PPAR-g inhibits cell proliferation by inducing G 0 /G 1 cell cycle arrest
To determine the mechanism of PPAR-g-induced growth inhibition in tumor cells, we first confirmed that the decrease in cell numbers after 72 h incubation with Tro was attributable to the inhibition of cell proliferation (Using CellTiter 96 Aqueous One Solution from Promega) (Figure 3a ). Inhibition of cell proliferation was dose-dependent in a manner consistent with the observed growth suppression noted earlier. To examine the potential contribution of apoptosis to the observed growth inhibition of Tro-treated A549 cells, we evaluated the apoptosis of cells under identical conditions by two different methods. First, we determined the numbers of cells with sub-G 1 DNA content at 72 h following Tro treatment using PI staining coupled with flow cytometric analysis. Cells undergoing apoptosis lose a portion of their DNA due to DNA fragmentation, resulting in an increase in the sub-G 1 population. Tro treatment did not have DNA content at all concentrations tested even after 72 h (Figure 5a ). We confirmed these data by another method based on the selective denaturation of DNA in apoptotic cells by formamide followed by the detection of denatured DNA with a single-stranded DNA (ssDNA) ELISA. Consistent with the sub-G 1 analysis, ssDNA-ELISA assay also did not detect any significant difference between Tro-treated and untreated A549 cells (Figure 5b ). This suggests that apoptosis is not responsible for the observed growth suppression induced by PPAR-g activation in A549 cells.
PPAR-g agonist induces sustained Erk1/2 activation and differentiation in A549 cells
The magnitude and duration of Erk1/2 activation, in part, determines the cell's responses to extracellular stimuli. Sustained activation of Erk1/2 is often associated with cellular differentiation and/or growth arrest in a cell-and tissue-specific manner (Roovers, 2000) . Consistent with this notion, we observed that the timedependent inhibition of A549 cell proliferation by Tro is associated with sustained Erk1/2 activation (Figure 6a ), an effect that temporally correlated with the downregulation of cyclin D (Figure 4 ). This indicates that sustained Erk1/2 activation may have a growth-inhibitory effect in NSCLC cells. This is contrary to widely observed tumor-promoting effects of Erk1/2 in a variety of other solid tumors. Furthermore, this suggests a novel mechanism by which Tro can suppress cell proliferation and induce differentiation-promoting pathways. Immunohistochemical analysis for phosphoErk1/2 in primary human tumors and surrounding normal lung tissue from 22 lung cancer patients revealed significantly less p-Erk1/2 staining in the tumors compared to normal tissue ( Figure 6b ). This further strengthens the concept that sustained Erk1/2 activation might be a growth-inhibitory signal in NSCLC cells. We further investigated the role of sustained Erk1/2 activation in PPAR-g-induced differentiation by studying the expression of two differentiation markers in the presence of a specific inhibitor that blocks Erk1/2 activation (U0126). The two differentiation markers studied were gelsolin and surfactant protein A (SP-A). Gelsolin is a general differentiation marker and it was shown that its expression was induced during PPAR-gmediated differentiation (Chang and Szabo, 2000) . SP-A is a lung-specific differentiation marker and its expression is reported to be decreased during PPAR-gmediated differentiation (Chang and Szabo, 2000) . Consistent with a previous report, Tro induced Gelsolin expression and decreased SP-A expression in A549 cells (Figure 6c ). Blocking Tro-induced Erk1/2 activation by (Figure 7b and c) . In addition, the metastatic lesions observed in the treated group were smaller and had more well-defined borders than those observed in the placebo group (Figure 7b and c) . PPAR-c in non-small-cell lung cancer VG Keshamouni et al
Discussion
Despite advances in the understanding of carcinogenesis, lung cancer remains the leading cause of cancer death in United States with a dismal 5-year survival rate. The development of effective therapeutic agents by adopting novel innovative approaches is urgently needed for the control of this disease. Inhibiting tumor cell growth by inducing differentiation is a promising approach to cancer therapy. The use of all-trans retinoic acid for the treatment of acute promyelocytic leukemia represents the first successful application of such an approach (Warrell et al., 1991) . However, this approach has not been successfully exploited for the treatment of solid tumors.
In the present study, we found a significant increase in the expression of PPAR-g in all human primary tumors tested compared to corresponding normal tissue by both immunohistochemistry and Western blotting. PPAR-g was also expressed in all the NSCLC cell lines tested. These data are consistent with previous studies in solid tumors (Elstner et al., 1998; Kubota et al., 1998; Mueller et al., 1998; Heaney et al., 2002) , including lung cancer (Chang and Szabo, 2000) , and suggest that high PPAR-g expression might serve as a potential tumor marker. To understand further the role of PPAR-g in lung tumorigenesis, we analysed PPAR-g activity in A549 lung adenocarcinoma cells. Even though A549 cells expressed PPAR-g protein, there was no significant PPAR-g activity in these cells in the absence of exogenous ligand, as determined by the luciferase-based reporter-gene transactivation assay. Nuclear hormone receptors in general undergo ubiquitination and proteosomal degradation upon activation by their ligand after target-gene transcription (Syvala et al., 1998; Alarid et al., 1999; El Khissiin and Leclercq, 1999; Nawaz et al., 1999; Zhu et al., 1999; Hauser et al., 2000) . In the absence of the ligand, they accumulate beyond normal basal levels of expression. The high level of PPAR-g expression observed in primary tumor specimens might reflect an accumulation of the receptor due to lack or insufficient amounts of a yet to be identified endogenous PPAR-g ligand. Treatment of cells with Tro, a PPAR-g agonist, induced PPRE-dependent reporter-gene transactivation in a dose-dependent manner, indicating that Tro induced PPAR-g activation. This also suggests that the PPAR-g protein present in these cells is not defective and can be exploited as a potential target for therapy using synthetic PPAR-g ligands. Concomitant with PPAR-g activation, Tro also induced growth arrest in A549 cells in a time-and dose-dependent manner, suggesting that Tro-induced growth arrest is PPAR-gdependent. In addition, A549 cells showed a dosedependent inhibition of proliferation with Tro treatment, indicating that growth arrest is predominantly due to a block in cellular proliferation. Flow cytometric analysis of cell cycle in Tro-treated A549 cells revealed a dose-dependent decrease in the number of cells in the S phase with a concomitant and proportionate increase in cells in G 0 /G 1 . This confirms that the inhibition of cellular proliferation is responsible for Tro-induced growth arrest. Two apoptotic assays failed to detect the induction of apoptosis, even after 72 h of Tro treatment. The lack of apoptosis in our study is in contrast to previous studies in breast and colon cancer cells (Elstner et al., 1998; Mueller et al., 1998; Sarraf et al., 1998) . However, it was in agreement with a recent study using NSCLC cell lines, which reported no significant apoptosis in the presence of serum after treatment with ciglitazone, another PPAR-g agonist (Chang and Szabo, 2000) , suggesting a unique response to PPAR-g activation in NSCLC cells.
Recent studies in breast cancer cells have shown that activated PPAR-g can downregulate cyclin D1 by transcriptional repression involving competition between PPAR-g and c-fos for a limited supply of coactivator p300 (Wang et al., 2001) . Cyclin D and E, in association with cdk4 and cdk2, respectively, are two critical regulators of cell cycle progression through G 1 . Extracellular signals that affect cell cycle typically control G 1 progression by regulating the expression of cyclins (Sherr, 1994) . Consistent with these observations and our cell cycle analysis data, we observed a dramatic downregulation of both cyclins D and E with Tro treatment in A549 cells. Although it is not a true hallmark of differentiation, the downregulation of cyclins and cdk activities by a variety of mechanisms is often associated with differentiation (Kiyokawa et al., 1994; Kranenburg et al., 1995) .
Interestingly, in addition to cyclin downregulation, we also observed sustained Erk1/2 activation, and modulation of differentiation markers. It is now well established that the duration and magnitude of Erk1/2 activation determines cell fate in response to extracellular stimuli, regulating functions as diverse as proliferation, differentiation, and morphogenesis (reviewed in Marshall, 1995; Gurdon et al., 1998) . In most epithelial cancers, sustained Erk1/2 activation has been associated with cellular transformation, proliferation, migration, and invasion of tumor cells (Nishida and Gotoh, 1993; Marshall, 1994; Krueger et al., 2001; Keshamouni et al., 2002) . Analysis of various human primary tumors revealed hyperactivation of Erk1/2 in malignant cells compared to surrounding normal tissue (Sivaraman et al., 1997; Mandell et al., 1998) . However, a recent study in human small-cell lung cancer cells reported that sustained Erk1/2 activation, achieved through the overexpression of an inducible Raf-estrogen receptor fusion protein, resulted in growth arrest (Ravi et al., 1998) . This is consistent with our data and clearly suggests that lung cancer cells may have a unique molecular circuitry compared to other cancers. Activation of PPAR-g triggers this pathway and induces growth arrest/differentiation via a hitherto unknown mechanism that requires further investigation. The concept of sustained Erk1/2 activation as a growthinhibitory signal is further strengthened by our demonstration of lower levels of phospho-Erk1/2 in human primary NSCLC tumor specimens compared to surrounding normal tissue.
Extending our in vitro data, we observed significant antitumor activity in vivo in response to treatment with Tro or Pio. Treatment with Tro or Pio also decreased spontaneous lung metastasis in our in vivo tumor model. The mechanism(s) for inhibition of metastasis need to be further investigated. Our current data suggest that inhibitory effects of PPAR-g ligands on cell proliferation may in part be responsible for decreased metastasis. In addition, we have observed the inhibition of angiogenic chemokines in tumor cells and decreases in blood vessel density in A549 tumors (manuscript under preparation). This may be another potential mechanism for the observed metastasis inhibition and it is consistent with a recent report on other antiangiogenic effects of PPARg (Panigrahy et al., 2002) . However, the precise mechanism(s) for inhibition of metastasis by PPAR-g ligands need to be further investigated. Current data, in conjunction with previous studies in other types of cancer, suggest that it is reasonable to explore the potential use of PPAR-g ligands, such as Tro or Pio, for the treatment of NSCLC. Given the relatively favorable toxicity profile of these drugs and the limited treatment options that are currently available for patients with NSCLC, there is now a compelling rationale to test these drugs in clinical trials either as single agents or in combination with more conventional chemotherapeutic agents.
Materials and methods
Cell culture
The A549 human lung adenocarcinoma cell line and H520 squamous cell carcinoma cell line were obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI-1640 medium with glutamine, supplemented with 10% FBS, penicillin, and streptomycin. All tissue culture media and media supplements were purchased from Life Technologies (Gaithersberg, MD, USA).
Tumor tissues and immunohistochemistry
Frozen and formalin-fixed, paraffin-embedded surgical sections of tumors from 22 patients with NSCLC (12 adenocarcinomas and 10 squamous cell carcinomas) were obtained from the University of Michigan Comprehensive Cancer Center (Ann Arbor, MI, USA). Total proteins were extracted from the frozen tissues in PBS containing a cocktail of protease inhibitors for mammalian tissue extractions from Roche biochemicals. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections using citratemicrowave antigen retrieval. Polyclonal antibody (H100) against PPAR-g from Santa Cruz Biotech (Santa Cruz, CA, USA), or monoclonal antibody against p-Erk1/2 from Cell Signaling (Beverly, CA, USA) was used. Histochemical analysis was performed using avidin-biotinylated peroxyidase technique using Vectastain kits from Vector Laboratories (Burlingame, CA, USA).
Western blotting
Crude protein extracts were obtained lysing 5 Â 10 6 cells in a buffer (50 mm Tris-HCl (pH 7.6), 1% Nonidet P-40, 2 mm EDTA, 0.5% sodium deoxycholate, 150 mm NaCl, 1 mm sodium orthovanadate, 2 mm EGTA, 4 mm sodium p-nitrophenyl phosphate, and 100 mm sodium fluoride) supplemented with protease inhibitors (leupeptin 0.5%, aprotinin 0.5%, and phenylmethylsulfonyl fluoride 0.02%). Samples containing 20 mg of total protein were electrophoresed on SDS-PAGE and transferred onto a nitrocellulose membrane by electroblotting. Membranes were later probed with antibodies as indicated, followed by horseradish peroxidase-conjugated mouse or rabbit secondary antibodies from Pierce (Rockford, IL, USA) and West Pico chemiluminescence detection reagents from Pierce (Rockford, IL, USA). Mouse monoclonal PPAR-g (E8) antibodies were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA), mouse monoclonal phosphoErk1/2 and mouse monoclonal b-actin antibodies were obtained from Sigma (St Louis, MO, USA), rabbit polyclonal Erk1/2 antibodies were obtained from Zymed laboratories (San Fransisco, CA, USA), and rabbit polyclonal cyclin D and mouse monoclonal cyclin E antibodies were obtained from NeoMarkers (Fremont, CA, USA).
Luciferase-based reporter-gene transactivation assays
Cells were seeded in 24-well plates at a density of 10 5 cells/well and allowed to reach 60-70% confluence. The cells were transfected with Lipofectamine (Gibco) in the absence of serum with 1 mg/well of either the PPAR-g-responsive reporter plasmid pFATP-(PPRE) 3 -tkLuc (FATP-derived PPARg response element with firefly luciferase gene under the control of a thymidine kinase promoter) or control plasmid (tk-Luc). The renilla luciferase plasmid (SV40-RLuc) (0.1 mg/well) was also transfected as an internal control for monitoring transfection efficiency and for normalizing the firefly luciferase activity. After 4 h of transfection, cells were washed and treated with PPAR-g ligands in the presence of serum. After 24 h, cells were lysed and the luciferase activity was assayed in the lysates using Promega's Dual-luciferase assay system according to the manufacturer's protocol.
Growth kinetics
For growth kinetics assessment, cells were incubated in the presence and absence of various agonists at indicated concentrations in six-well plates and cell numbers were monitored for 72 h by counting cells every 24 h. Cell counting was performed by detaching the cells in 1 ml of trypsin, and 200 ml of detached cells was diluted in 20 ml of Isotone solution (Beckman Coulter, Inc.) and cell numbers were counted using a Beckman Coulter counter.
Cell proliferation
Cell proliferation was measured using Promega's CellTiter 96 Aqueous One Solution cell proliferation assay according to the manufacturer's protocol (Promega). It is based on the cellular conversion of a tetrazolium salt into a soluble formazon product as a measure of proliferation. In brief, 5000 cells were plated in each well of a 96-well plate in RPMI-1640 medium with 10% serum. After 24 h, cells were treated with various concentrations of PPAR-g agonists. After 48 h of incubation with agonists, the aqueous one solution reagent was added and incubated for 2-3 h. The intensity of the color was measured at 490 nm using a 96-well plate reader.
Cell cycle analysis
Cell cycle analysis by flow cytometry was performed by detaching cells from culture plates with trypsin, washing 2 Â with PBS and fixing in 80% ethanol-PBS. After 30 min of incubation at 41C, cells were centrifuged for 5 min at 3000 g. The cell pellet was resuspended and incubated for 30 min in 0.05 mg/ml PI, 1 mm EDTA, 0.1% Triton X-100, and 1 mg/ml RNAse A in PBS. The suspension was then analysed on a Becton Dickinson FACScan. The ratio of cells in the G 0 /G 1 , S, and G 2 /M phases of cell cycle were determined by their DNA content.
Apoptosis
Apoptosis was analysed by two different methods: (1) Sub-G 1 DNA analysis: In this method after 72 h of Tro treatment, free nuclei stained with PI were obtained from hypotonic lysis of A549 cells in a buffer containing sodium citrate (0.1%), Triton X (0.1%), RNAse (100 mg/ml), and PI (50 mg/ml) and analysed on a Becton Dickinson FACScan. Cells undergoing apoptosis will lose part of their DNA due to DNA fragmentation; such cells are detected as sub-G 1 population.
(2) ssDNA ELISA: This method is based on the selective denaturation of DNA in apoptotic cells by formamide and detection of denatured DNA with monoclonal antibody to ssDNA. The assay was performed following the manufacturer's protocol using an ssDNA apoptosis ELISA kit from Chemicon International, Inc.
Tumor xenografts in SCID mice
CB17-SCID mice (six-week-old) were subcutaneously injected with A549 cells (1 Â 10 6 in 100 ml) on either side of the dorsal flank. Six mice in each group were treated once daily by oral gavage for 8 weeks with Tro (200 mg/kg) or Pio (25 mg/kg) or placebo after tumor cell injection. Drugs were formulated by suspending them in an aqueous solution of 2% carboxymethylcellulose and 0.2% Tween 20 and then sonicating for 5 min. Tumor growth was monitored by weekly measurements with calipers. After 8 weeks, animals were killed and tumors were dissected and measured for three-dimensional size. Whole lungs were removed from the mice, fixed in paraformaldehyde, and examined for metastases. After counting the number of metastases, lungs were embedded in paraffin for thin sectioning. Thin whole lung sections were stained with H&E and the number and character of metastases were microscopically evaluated.
Three methods were used to assess in vivo antitumor activity: (1) tumor growth delay, in terms of the T-C value, in which T is the median time (in days) required for the treatment group tumors to reach a predetermined size, and C is the median time (in days) for the placebo group tumors to reach the same size, using 1500 mm 3 as the target tumor size; (2) tumor cell kill, in terms of log 10 cell kill calculated using the formula, log 10 kill (total) ¼ (T-C)/(3.32 Â T d ), in which T-C is the tumor growth delay (in days) as described above and T d is the tumor volume doubling time (in days) estimated from control group tumors during growth (500-1500 mm 3 ); and (3) tumor growth inhibition, calculated as 100À(T/C Â 100), in which the median tumor size in each group (C, placebo; T, treatment) was determined at a time when the placebo group's median tumor size was 1500 mm 3 . 
